Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CLSN

Imunon (CLSN) Stock Price, News & Analysis

Imunon logo

About Imunon Stock (NASDAQ:CLSN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$1.95
$2.63
52-Week Range
N/A
Volume
711 shs
Average Volume
150,471 shs
Market Capitalization
$13.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Remove Ads
Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Stock News Headlines

Imunon Inc IMNN
CLSN.L Regulatory News
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
See More Headlines

CLSN Stock Analysis - Frequently Asked Questions

Imunon, Inc. (NASDAQ:CLSN) announced its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%.

Shares of Imunon reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Acasti Pharma (ACST), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
8/15/2022
Today
3/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLSN
Employees
27
Year Founded
1982

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,770,000.00
Net Margins
-5,229.80%
Pretax Margin
-5,506.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Price / Cash Flow
N/A
Book Value
$9.66 per share
Price / Book
N/A

Miscellaneous

Free Float
6,768,000
Market Cap
$13.91 million
Optionable
Optionable
Beta
2.27

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CLSN) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners